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Abstract
Genetic events underlying pathogenesis of nodal and extranodal marginal zone
lymphoma are not completely understood. We report here a novel t(X;14)
(p11.4;q32.33) identified in 4 lymphoma cases: 2 with a mucosa-associated
lymphoid tissue lymphoma, one with a nodal marginal zone lymphoma and
one with gastric diffuse large B-cell lymphoma. In all cases, lymphoma evolved
from a previous auto-immune disorder. Fluorescence in situ hybridization and
molecular studies showed that t(X;14), which is mediated by immunoglobulin
heavy chain locus, targets the GPR34 gene at Xp11.4. Upregulation of GPR34
mRNA and aberrant expression of GPR34 protein has been demonstrated in
3 presented cases by quantitative real-time polymerase chain reaction and
immunohistochemistry, respectively. GPR34 belongs to the largest family of
cell surface molecules involved in signal transmission that play important roles
in many physiological and pathological processes, including tumorigenesis.
Although functional conse...
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Introduction
Extranodal marginal zone lymphoma (MZL) of mucosa-
associated lymphoid tissue (MALT) and nodal MZL are recog-
nized as distinct entities in the World Health Organization
classification of lymphoid tumors.1 So far, genetic features of
both lymphoma entities have not been well characterized. It
has been shown, however, that approximately 25% of MALT
lymphoma cases are hallmarked by recurrent chromosomal
translocations. The most frequent is t(11;18)(q21:q21) leading
to an API2 -MALT1 fusion. Less common translocations
include IGH-mediated t(1;14)(p22;q32), t(14;18)(q32;q21) and
t(3;14)(p14;q32) targeting the BCL10, MALT1 and FOXP1
genes, respectively.2 Notably, the BCL10 and MALT1 proteins
play a physiological role in antigen receptor mediated activa-
tion of the nuclear factor-kB (NF-kB) signaling pathway,
known to be implicated in tumor growth, survival and
chemoresistance.3 Aberrant activation of this pathway not
only underlies MALT lymphomas with t(1;14), t(11;18) and
t(14;18), but also cases with loss/inactivation of TNFAIP3/A20
(6q23), a known repressor of NF-kB4 and activating mutations
of MYD88.5
We report here a novel translocation, t(X;14)(p11.4;q32.33),
that was identified in 2 cases of MALT lymphoma, and single
cases of nodal MZL and gastric diffuse large B-cell lymphoma
(DLBCL).
Design and Methods
Patients
Patients’ samples were selected from the lymphoma database of the
Center for Human Genetics, KU Leuven, Leuven. Research on existing
material, used anonymously, was approved by the Ethics Committee
from the KU Leuven.
Immunohistochemistry
Immunohistochemistry (IHC) using antibody against GPR34 (Atlas
Antibodies AB, Stockholm, Sweden) was performed on paraffin-
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Genetic events underlying pathogenesis of nodal and extran-
odal marginal zone lymphoma are not completely understood.
We report here a novel t(X;14)(p11.4;q32.33) identified in 4
lymphoma cases: 2 with a mucosa-associated lymphoid tissue
lymphoma, one with a nodal marginal zone lymphoma and
one with gastric diffuse large B-cell lymphoma. In all cases,
lymphoma evolved from a previous auto-immune disorder.
Fluorescence in situ hybridization and molecular studies
showed that t(X;14), which is mediated by immunoglobulin
heavy chain locus, targets the GPR34 gene at Xp11.4.
Upregulation of GPR34 mRNA and aberrant expression of
GPR34 protein has been demonstrated in 3 presented cases by
quantitative real-time polymerase chain reaction and
immunohistochemistry, respectively. GPR34 belongs to the
largest family of cell surface molecules involved in signal trans-
mission that play important roles in many physiological and
pathological processes, including tumorigenesis. Although
functional consequences of t(X;14) have not been identified,
our studies suggest that up-regulated GPR34 activate neither
nuclear factor-kB nor ELK-related tyrosine kinase.
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ABSTRACT
embedded tissue sections. As positive controls, normal testis and
bone marrow biopsies from patients with mastocytosis were
used. Sections were stained according to the manufacturer’s rec-
ommendations, and IHC results were visualized using the En
Vision system (Dako Denmark A/S).  
Cytogenetic and fluorescence in situ
hybridization analysis 
Conventional G-banding chromosomal analysis and fluores-
cence in situ hybridization (FISH) followed routine methods.
Probes applied for FISH included LSI IGH (Abbott Molecular,
Wiesbaden, Germany) and 16 home-brewed bacterial artificial
chromosome (BAC) clones selected from www.ensembl.org (Online
Supplementary Figure S1) and labeled with SpectrumOrange- and
SpectrumGreen-d-UTP (Abbott Molecular) using random priming.  
Agilent CGH-array 
The cases were analyzed using Agilent 244k CGH microarrays
(Agilent Technologies, Santa Clara, CA, USA). One µg of both ref-
erence and tumor DNA was labeled using Agilent Genomic DNA
Labeling Kit, mixed with a provided hybridization solution and
hybridized to the array, according to the manufacturers’ protocol.
After 40 h of hybridization and subsequent washing steps, the
arrays were scanned with the GenePix scanner and analyzed using
the Feature extraction 9.5.3.1 and the DNA analytics 4.0 software.
Quantitative RT-PCR
RNA isolation and cDNA synthesis were performed using stan-
dard protocols. The BJAB cell line was transfected with an eukary-
otic expression construct for GPR34 (pcDNA3.1) via electropora-
tion to allow stable GPR34 expression, and single positive clones
were obtained via clonal dilution and selection with G418.
Quantitative RT-PCR was performed with the LightCycler 480
SYBR Green I master mix (Roche Diagnostics Belgium, Vilvoorde,
Belgium) and analyzed using the comparative dCt method. Primer
sequences are shown in the Online Supplementary Table S1. In all
experiments, the housekeeping gene HPRT1 was used as a refer-
ence control.
Western blot analysis
SDS-PAGE and Western blot analysis followed standard proto-
cols. Antibodies used for immunodetection of phospho-IκBα
(Ser32/36, clone 5A5) and phospho-p44/42 MAPK
(Thr202/Tyr204, clone D13.14.4E) were from Cell Signaling
Technology (Danvers, MA, USA). Antibody against ERK2 (p42)
(ERK 2 (D-2): sc-1647) was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The signal was visualized with the enhanced
chemoluminescence (ECL) system (Perkin Elmer, Zaventem,
Belgium) on an LAS 3000 mini gene system (Fuji) using the
Advanced Image Data Analyzer (AIDA) Software (Raytest
BeNeLux B.V., Tilburg, The Netherlands).
Table 1. Relevant clinical and cytogenetic findings.
Case Clinical and genetic features 
Sex/ Diagnosis Underlying LDH Performance Ann Sites of Initial Follow up Status Sample/ Karyotype1
Age conditions status Arbor involvement therapy and (months) status
(months before Nodal Extra-nodal response
diagnosis 
of NHL) 
1 F/66 MALT Sjögren  normal 2 IV A - lung surgery,  54 alive, in  CL /D 48,X, 
lymphoma syndrome15 CR 2nd CR* +X,t(X;14)
(p11.4;q32.33), dup(9)
(q33.3q34.3), der(14)
t(X;14)(p11.4;q32.33)
[1],+del(21)
(q11.2q22.11)[cp4]
2 F/69 MALT Sjögren  elevated 0 IV A + lung CVP, CR 87 Dead, 1st LN/D 46,X,t(X;14)
lymphoma syndrome8 CR Reason (p11.4;q32.33),
of death: der(21)dup(21)
anal (q21.2q22.2)del(21)
spinocellular (q22.3q22.3),dup(22)
carcinoma (q11.23q13,2)[4]
LN/P 46,idem[ 8]
3 F/82 nodal MZL (i) normal 0 II A +2 - Leukeran 42 alive, in LN/D 46,X,t(X;14)
leukocytoclastic -Medrol, CR 1st CR (p11.4;q32.33),inv(1)
vasculitis (p32q21), t(2;2)
(biopsy-proven); (p23;q33)[3],t(4;6)
(ii) sensoric (q31;q27),der(14)
motor axonal t(X;14)(p11.4;q32.33)
polyneuropathy [3] [cp8]
of unknown 
origin;52
4 M/82 DLBCL chronic UN UN UN - stomach surgery, 21 Dead due to S/D 46,t(X;14)
gastritis, CEOP, UN a progressive (p11.4;q32.33),
H P- negative disease Y[cp18]
F: female; M: male; MALT: mucosa associated lymphoid tissue; MZL: marginal zone lymphoma; DLBCL: diffuse large B-cell lymphoma;  HP: Helicobater. Pylori; NE: not evaluated; CR: complete remis-
sion; CVP: cyclophosphamide, vincristine, prednisone; CEOP: cyclophosphamide, epirubicin, vincristine, prednisone; D: diagnosis; P,: progression; CL: coin lesion; LN: lymph node; S: stomach. 1Karyotype
corrected after FISH and aCGH. Chromosomal aberrations are presented in accordance with the International System for Human Cytogenetic Nomenclature6; 2cervical LN; UN. unknown.
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Results and Discussion 
The relevant cytogenetic, clinical and histological charac-
teristics of the reported cases are shown in Table 1. There
were 3 females and one male, age ranging from 66 to 82
years (median 75 years). All patients received an initial ther-
apy. Two patients are alive after 42-54 months from diagno-
sis and 2 have died, either from progressive lymphoma, or
from an unrelated cause (other tumor). In each patient,
t(X;14) was identified at the time of lymphoma diagnosis.
The translocation occurred as the sole abnormality in one
case (# 4) and was accompanied by 2 to 4 additional chro-
mosomal abnormalities in other cases. Of note, a subclonal
appearance of an additional der(14)t(X;14) was observed in
cases 1 and 3 (Table 1 and Figure 1A). The t(X;14)-related
rearrangement of IGH was proven by FISH with LSI IGH
(Figure 1B). To identify the partner gene targeted by t(X;14),
metaphase FISH BACs-walking approach was applied in
case 4. In total, 12 BAC clones from the Xp21.3-q11.22 (27-
54 Mb) region were used and the breakpoint was narrowed
down to the region of CASK at Xp11.4 (Online
Supplementary Figure S1A). Given that intron 5 of CASK
houses the GPR34 and GPR82 genes (Online Supplementary
Figure S1B), 4 additional BAC clones covering CASK were
further applied. Eventually, the breakpoint was mapped in
the region flanked by RP11-204C16 (covering GPR34 and
GPR82) and RP5-1174J21 that hybridized to der(14) and
der(X), respectively (Figure 1C). The remaining cases
showed the Xp11.4 breakpoint in the same interval.
FISH was followed by qRT-PCR analysis of 5 candidate
genes located telomeric to the Xp11.4 breakpoint and
translocated to der(14) (GPR82, GPR34, CASK, DDX3X,
USP9) performed in 3 available cases (#1-3). As control,
RNA from non-malignant spleen was used. This analysis
showed that only one of the analyzed genes, GPR34, was
up-regulated 11 to 100-fold in the studied cases (Online
Supplementary Figure S1C). Further immunostaining with
anti-GPR34 serum showed expression of GPR34 protein in
3 out of the 4 analyzed cases (Figure 1D and E).
Unfortunately, no archive material from case 4, negative by
IHC, was available for qRT-PCR. Whether lack of reactivi-
ty with this serum was caused by a technical failure or a
low expression level of the GPR34 protein by neoplastic
cells, or by activation of another Xp11.4 gene remains
unknown. 
To check whether any cryptic recurrent genomic imbal-
ances were associated with t(X;14), all 4 cases were subject-
ed to Agilent oligonucleotide 244K array analysis. An aver-
age 24 copy number alterations (CNA) (range 11-32) per
case were detected, including aberrations previously identi-
fied by cytogenetics (Online Supplementary Figure S2). Most
of the CNA were smaller than 1 Mb and overlapped with
m. Baens et al.
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Figure 1. Examples of cytogenetic, FISH, IHC
and molecular studies. (A) Partial karyotype
of case 3 showing t(X;14)(p11.4;q32.33) and
an extra copy of der(14). (B and C) Examples
of FISH analysis of case 3 using LSI IGH and
BAC clones flanking the Xp11.4 region
(RP11-204C16-SO/RP11-1174J21-SG),
respectively. (D) H&E staining of case 3. (E)
IHC with GPR-34 serum in case 3. (F)
Immunoblot analysis of cases 1-3 with anti-
bodies that specifically recognize phosphory-
lated IkBα and p42/p44 MAPK (ERK).
Lysates of stimulated Jurkat cells were used
as positive control. Blots were re-probed with
MAPK p44 to confirm even protein loading.
FISH images were acquired with a 63x/1.40
oil-immersion objective in an Axioplan 2 fluo-
rescence microscope equipped with an
Axiophot 2 camera (Carl Zeiss Microscopy,
Jena, Germany) and a MetaSystems Isis
imaging system (MetaSystems). H&E  and
IHC images were captured with a Leica DMLB
microscope (Leica, Wetzlar, Germany) using a
Leica PL FLUOTAR lens (40x/0.70) and a
Leica DC200 camera. Images were imported
directly into PowerPoint (Microsoft,
Redmond, WA, USA) using the Leica DC200
camera software (version 2.51).
A
B
C F
E
D
regions of CNVs. Those not associated with CNVs (e.g.
del(9)(p24)/1.39 Mb in case 4) were random. The only
recurrent aberration was dup(21)(q24qter) (41561927-
46914886) detected in cases 1 and 2 (Online Supplementary
Figure S3). These data support the concept that t(X;14) was
the driving genetic aberration in the presented lymphomas. 
The t(X;14) was identified in 2 of 61 (3.3%) cases of
MALT lymphoma, in one of 43 (2.3%) cases of nodal MZL
and one of 19 (5.2%) cases of extranodal DLBCL with
clonal chromosomal abnormalites analyzed in our institu-
tion during the last 16 years. To search for additional cases
with t(X;14), break apart FISH probes for IGH and CASK
were applied in 10 cases of MALT lymphoma with
unknown karyotype originating from the lung (n=3),
stomach (n=2), spleen (n=2), parotid gland (n=2) and
lachrymal gland (n=1). No chromosomal breaks in these
loci were found. Moreover, we reviewed the available
global expression data of the previously studied 6 t(11;18)-
positive and 8 t(11;18)-negative gastric MALT lymphomas
(Gene expression Omnibus, accession n. GSE 25550;
www.ncbi.nlm.nih.gov/projects/geo/). The level of GPR34
mRNA expression in these cases was comparable with that
of control non-malignant spleens (10.045 vs. 9.9725 vs.
10.432, respectively). Additional IHC performed on 6 gas-
tric and 9 pulmonary MALT lymphoma cases showed lack
of GRP34 expression in 14 cases. Interestingly, in case of
transformed MALT lymphoma, an aberrant expression of
GPR34 was found exclusively in a large cell component
showing an extra copy of GPR34 by FISH (data not shown). 
As constitutive NF-kB activity is frequently associated
with B-cell lymphoma development,3 we examined
whether the NF-kB pathway was active in 3 lymphomas
with t(X;14) from which material was available. In all of
them, Western blot analysis showed phosphorylation of
the NF-kB inhibitor protein Ik-Bα (Figure 1F) which indi-
cates its degradation and is a hallmark of activation of
NF-kB pathway. Jurkat T cells stimulated with
PMA/Ionomycin served as a positive control. Quantitative
RT-PCR further confirmed upregulation of a number of NF-
kB target genes in t(X;14) lymphoma samples, with tran-
script levels comparable to a t(11;18)-positive MALT lym-
phoma (Online Supplementary Figure S4A). Whether GPR34
activates NF-kB is unknown. Knock-out studies in mice
revealed a physiological role for GPR34 in the immune
response7 which is tightly regulated by NF-kB. To examine
the role for GPR34 in NF-kB activation, we over-expressed
GPR34 in the B-cell lymphoma cell line BJAB, in which the
NF-kB pathway is relatively quiescent. Although GPR34
transcript levels increased 40 to 800-fold, the set of NF-kB
target genes was not up-regulated, in contrast to its induced
upregulation by overexpression of API2-MALT1 or mutant
CARD11 (L232LI), known activators of NF-kB signaling in
B cells (Online Supplementary Figure S4B). These data suggest
that activation of NF-kB signaling in MALT lymphomas
with t(X;14) is not mediated by GPR34 overexpression and
most likely involves other mechanisms.
In summary, our study provides evidence that the new
IGH-mediated t(X;14)(p11.4;q32) is a primary aberration
involved in the pathogenesis of B-NHL, including extran-
odal and nodal MZL, and gastric DLBCL. This transloca-
tion and the well known t(1;14), t(3;14), t(11;18), and
t(14;18) are mutually exclusive in MALT lymphoma. Of
note, all 4 reported patients had an underlying disorder,
including Sjögren’s syndrome (case 1 and 2), a leukocyto-
clastic vasculitis and polyneuropathy (case 3), and HP-neg-
ative chronic gastritis with intestinal metaplasia (case 4).
The observation of Sjögren’s syndrome in both MALT
lymphoma cases remains in line with the general concept
of MALT lymphoma development suggesting that this
neoplasm arises as a result of chronic B-cell stimulation.8
Molecular analysis showed that t(X;14) targets GPR34.
Upregulation of GPR34 mRNA and protein was demon-
strated by qRT-PCR and IHC, respectively, performed in 3
cases. The finding of a subclonal gain of der(14)t(X;14) in 2
cases suggests that an extra dosage of the GPR34 product
may provide a growth advantage for tumor cells. GPR34,
like the neighboring GPR82, codes for a G-protein coupled
receptor that belongs to the largest family of cell surface
molecules involved in signal transmission.9 These integral
membrane proteins contain 7 putative transmembrane
domains and mediate signals to the interior of the cell.
They activate heterotrimeric G proteins that in turn acti-
vate various effector proteins, eventually leading to the
activation of multiple intracellular signaling pathways and
a physiological response. An aberrant expression and activ-
ity of GPRs has been implicated in a wide spectrum of dis-
eases, including tumors/malignancies.10 Importantly, due to
their unique structure, localization and ligand binding
activity, GPRs have been extensively used for drug devel-
opment and are the most common targets of commercial
drugs.9
GPR34 was originally cloned from a human fetal brain
cDNA library based on the platelet-activating factor (PAF)
receptor sequence.11,12 The receptor mRNA is ubiquitously
expressed in all human tissues, particularly in placenta,
brain and spleen.13 Recent studies suggest that GPR34,
found to be abundantly expressed in mast cells, is the func-
tional mast cell receptor for lysophosphatidyl-L-serine
(lysoPS).14 The latter molecule seems to stimulate degranu-
lation of mast cells. High functional expression of GPR34 in
mast cells suggests that the receptor is involved in a basic
function of these cells and is possibly activated in damaged
and inflamed tissues. Genetic studies in mice, however, did
not confirm that the known effects of lyso-PS, such as mast
cell degranulation and cell migration, are mediated by
GPR34. However, GPR34 function appeared to be required
for an adequate immune response, suggesting that its
upregulation could contribute to lymphomagenesis.7
So far, there has been only a preliminary report of
involvement of GPR34 in tumorigenesis by Novak et al.
(ASH abstract15). The authors presented one case of MALT
lymphoma with the same t(X;14)/IGH-GPR34 rearrange-
ment and suggested a role for ERK signaling in tumor
development. Hela cells with stable overexpression of
GPR34 but not a signaling deficient mutant indeed dis-
played increased phosphorylation of ERK1/2. In addition,
proliferation was significantly higher in GPR34 over-
expressing cells and was hampered by MAPK inhibitor. In
our model of BJAB cells over-expressing GPR34, however,
phosphorylation of ERK was not observed (Online
Supplementary Figure S5) which may suggest a cell type-
dependent effect. The observation that ERK is also not con-
stitutively phosphorylated in the present MALT lym-
phomas with t(X;14) (Figure 1F) further questions its role in
the pathogenesis of these tumors.
In conclusion, we identified GPR34 as a new player of B-
NHL pathogenesis. The gene is recurrently targeted by the
IGH-mediated t(X;14)(p11.4;q32.33) associated with
MZ/MALT lymphoma evolving from a previous auto-
immune disorder. The functional consequences of t(X;14)
t(X;14)(p11.4;q32.33) in MZL
haematologica | 2012; 97(2) 187
remain elusive, but our data indicate that up-regulated
GPR34 activates neither NF-kB nor ERK. Further studies
are required to determine GPR34 natural ligand(s) and sig-
nal pathways. Given that G protein-couple receptors
(GPCR) represent the very important therapeutic targets
and new GPCR-based drugs are under development,9 lym-
phoma patients with t(X;14) might benefit in future from
cancer-tailored treatments. 
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